- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07947537
Duodenal Mucosa Responses to Endoscopic Food Challenges in Patients With Inflammatory Bowel Disease and Irritable Bowel Syndrome With Self-reported Food Intolerances: A Feasibility Study (DRFC)
Duodenal Responses to Food Challenges in Patients With Self-reported Food Intolerances: a Feasibility Study
The goal of this study is to investigate the feasibility of using intravenous fluorescein during a standard endoscopy-along with a laser to activate it and an optical filter-to identify changes in the duodenal mucosa after a controlled food challenge in individuals with IBD and IBS who experience food intolerances. The main questions it aims to answer are:
- Is this technique feasible approach to assess food intolerances in patients with IBD and IBS?
- Does patients with IBD and IBS exhibit acute tissue changes upon exposure to specific food antigens?
Researches will compare the food antigen to a placebo solution (saline solution without an antigen) to see if the reaction in the tissue is different.
Participants will:
- Answer questionnaires.
- Provide a blood and stool sample.
- Take an allergy test.
- Undergo an upper endoscopy.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a prospective, double-arm, randomized feasibility study. This study will recruit patients with Inflammatory Bowel Disease (IBD) in remission and patients with Irritable Bowel Syndrome (IBS), who self-report food intolerances. All participants will undergo an upper endoscopy with the administration of a food challenge solution (cow's milk protein or placebo), intravenous fluoresceine administration, biopsies and fluid collection.
Upon signing informed consent, participants will be enrolled in the study. Following enrollment, participants will be randomized in a 2:1 ratio to receive either a food challenge with a cow's milk protein solution or a placebo solution during the upper endoscopy, which will occur in visit 3.
During the first visit, participants will complete questionnaires covering demographics, medical history, gastrointestinal symptoms (using the Gastrointestinal Symptoms Rating Scale), and food intolerances. Blood samples will be collected from all participants, and IBD patients will additionally provide stool samples for fecal calprotectin measurement.
In the second visit, participants will be evaluated by an experienced allergologist, and a skin prick test will be conducted to rule out an allergy to cow's milk protein.
After completing these initial evaluations, participants will be scheduled for visit 3. In preparation for this visit, participants will be instructed to avoid consuming any products containing cow's milk for five days prior. During visit 3, an upper endoscopy will be performed. Through the endoscope's working channel, either a cow's milk protein solution or a placebo solution will be delivered to the third portion of the duodenum. Additionally, eight biopsies and a fluid sample will be collected from this area. A permeability test will also be performed using intravenous fluorescein, and the procedure will be recorded on video.
Following the third visit, a follow-up phone call will be conducted to assess any symptoms that participants may have experienced post-procedure.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: David Armstrong, MD
- Numéro de téléphone: 76404 905 521 2100
- E-mail: armstro@mcmaster.ca
Sauvegarde des contacts de l'étude
- Nom: Liam Rondeau, PhD
- Numéro de téléphone: 76404 19055259140
- E-mail: rondeaul@mcmaster.ca
Lieux d'étude
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 4K1
- McMaster University Medical Centre
-
Chercheur principal:
- David Armstrong, MD
-
Contact:
- David Armstrong, MD
- Numéro de téléphone: 76404 905 521 2100
- E-mail: armstro@mcmaster.ca
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Confirmed diagnosis of IBD (UC or CD) and under clinical remission for at least 3 months, OR confirmed diagnosis of IBS (any subtype) by Rome IV criteria.
- Report having one or more food intolerance.
- Able to provide informed consent.
Exclusion Criteria:
- Presence of a known food allergy.
- Presence of serum IgE positivity or a positive skin-prick test to cow's milk.
- Known allergy to fluorescein.
- Diagnosis of celiac disease.
- Positive IgA TTG antibodies.
- Pregnancy or breastfeeding.
- Presence of a contraindication for an upper endoscopy.
- History of surgery involving the upper gastrointestinal tract.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Cow's milk protein solution
A solution with 5 mL cow's milk protein fraction mixed with 50% sterile water applied onto the duodenal mucosa one time during an upper endoscopy. |
Participants will undergo an upper gastrointestinal endoscopy under conscious sedation. Standard monitoring will be used, and a high-definition video system will record the procedure. A Fuji colonoscope fitted with a transparent distal cap and optical filter will guide the examination up to the proximal jejunum. Upon reaching the duodenum (D3), 5 mL of 10% fluorescein and 40 mg methylscopolamine will be injected intravenously. Immediately after, either a cow's milk protein solution or a placebo solution will be applied to the duodenal mucosa via the endoscope channel. A laser will excite the fluorescein, and real-time video will be recorded. Duodenal fluid (1-1.5 mL) will be collected with an ERCP catheter, and eight biopsies will be obtained for analysis
Autres noms:
|
|
Comparateur placebo: Placebo solution
A solution with 18 mL sterile water + 2 mL simethicone applied onto the duodenal mucosa one time during an upper endoscopy. |
Participants will undergo an upper gastrointestinal endoscopy under conscious sedation. Standard monitoring will be used, and a high-definition video system will record the procedure. A Fuji colonoscope fitted with a transparent distal cap and optical filter will guide the examination up to the proximal jejunum. Upon reaching the duodenum (D3), 5 mL of 10% fluorescein and 40 mg methylscopolamine will be injected intravenously. Immediately after, either a cow's milk protein solution or a placebo solution will be applied to the duodenal mucosa via the endoscope channel. A laser will excite the fluorescein, and real-time video will be recorded. Duodenal fluid (1-1.5 mL) will be collected with an ERCP catheter, and eight biopsies will be obtained for analysis
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Procedure completition
Délai: From the start of the endoscopy up to 10 minutes after the food challenge
|
Successful completion of the procedure including sample collection, administration of the food challenge, and development of a reaction in the duodenal mucosa. A positive reaction in the mucosa will be defined by the presence of intraepithelial lymphocytes >25/100 epithelial cells. |
From the start of the endoscopy up to 10 minutes after the food challenge
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Signes et symptômes digestifs
- Maladies intestinales
- Maladies du système digestif
- Maladies gastro-intestinales
- Maladies du côlon
- Gastro-entérite
- Maladies du côlon, fonctionnelles
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Intolérance alimentaire
- Syndrome de l'intestin irritable
- Maladies intestinales inflammatoires
- Techniques d'investigation
- Manipulation des échantillons
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Procédures chirurgicales, opératoires
- Procédures chirurgicales mini-invasives
- Techniques cytologiques
- Cytodiagnostic
- Techniques de diagnostic, chirurgicale
- Techniques de diagnostic, système digestif
- Endoscopie
- Procédures chirurgicales du système digestif
- Biopsie
- Endoscopie, système digestif
Autres numéros d'identification d'étude
- 18305
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .